Solution structure of iron(III)-anthracycline complexes

Journal of Medicinal Chemistry

Volumn 42, Issue 15, 1999, Pages 2844-2851

  Fiallo, Marina M L ^a   Drechsel, Hartmut ^a,b   Garnier Suillerot, Arlette ^a   Matzanke, Berthold F ^c   Kozlowski, Henryk ^c  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; FERRIC ION; IDARUBICIN; LIGAND; METAL ION;

ABSORPTION; ARTICLE; CHELATION; CIRCULAR DICHROISM; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; MOSSBAUER SPECTROSCOPY; STOICHIOMETRY;

ANTINEOPLASTIC AGENTS; CIRCULAR DICHROISM; DIMETHYLFORMAMIDE; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; IDARUBICIN; IRON; IRON CHELATING AGENTS; K562 CELLS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, MOSSBAUER; WATER;

EID: 0033614948     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981057n     Document Type: Article

References (46)

1. Gottesman, M. M.; Pasten, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
2. Arcamone, F.; Penco, S. In Anthracycline and Anthracenedione-based Anticancer Agents; Lown, J. W., Ed.; Elsevier: Amsterdam, 1988; pp 1-54.
3. 2) (ethylenediamine)bis[propyl(R-benzylimino)]metal(III) cat-ions. J. Med. Chem. 1996, 39, 3483-3490.
4. Goldberg, D. E.; Sharma, V.; Oksman, A.; Gluzman, I. Y.; Wellems, T. E.; Piwnica-Worms, D. Probing the chloroquine resistance locus of Plasmodium falciparum with a novel class of multidentate metal(III-) coordination complexes. J. Biol. Chem. 1997, 272, 6567-6572.
5. Kessel, D. Transport of an iron: anthracycline complex by murine leukemia cells. Cancer Lett. 1988, 42, 213-218.
6. Fiallo, M.; Laigle, A.; Garnier-Suillerot, A.; Amirand, C.; Ballini, J. P.; Chinski, L.; Dusquesne, M.; Jolles, B.; Sureau, F.; Turpin, P. Y.; Vigny, P. Interactions of iron-anthracycline complexes with living cells: a microspectrofluorometric study. Biochim. Biophys. Acta 1993, 1177, 236-244.
7. Hatcher, E. L.; Alexander, J. M.; King, Y. J. Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells. Biochem. Pharmacol. 1997, 53, 747-754.
8. Eliot, H.; Gianni, L.; Myers, C. Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry 1984, 23, 928-936.
9. Cullinane, C.; Phillips, D. R. Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. Biochemistry 1990, 29, 5638-5646.
10. Taatjes, D. J.; Gaudiano, G.; Koch, T. Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts. Initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/ NADH/iron, or glutathion/iron. Chem. Res. Toxicol. 1997, 10, 953-961.
11. M. M. L. Fiallo, Ph.D. Thesis, Université Paris Nord, 1986.
12. Fiallo, M. M. L.; Tayeb-Bel Haj, H.; Garnier-Suillerot, A. Degradation of anthracycline antitumor compounds catalyzed by metal ions. Metal-Based Drugs 1994, 1, 183-193.
13. Gelvan, D.; Berg, E.; Saltman, P.; Samuni, A. Time-dependent modifications of ferri-adriamycin. Biochem. Pharmacol. 1990, 39, 1289-1295.
14. Beijnen, J. H.; van der Houven, O. A. G. J.; Underberg, W. J. M. Aspects of the degradation kinetics of doxorubicin in aqueous solution. Int. J. Pharm. 1986, 32, 123-131.
15. Beijnen, J. H.; Potman, R. P.; van Ooijen, R. D.; Driebergen, R. J.; Voskuilen, M. C. H.; Renema, J.; Underberg, W. J. M. Structure elucidation and characterization of daunorubicin degradation products. Int. J. Pharm. 1987, 34, 247-257.
16. Fiallo, M.; Laigle, A.; Borrel, M. N.; Garnier-Suillerot, A. Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium within sensitive and resistant cells. Biochem. Pharmacol. 1993, 45, 659-665.
17. Gosalvez, M.; Blanco, M. F.; Vivero, C.; Valles, F. Quelamycin. A new derivative of adriamycin with several possible therapeutic advantages. Eur. J. Cancer 1978, 14, 1185-1190.
18. Bachur, N.; Friedman, R. D.; Hollenbeck, R. G. Physicochemical characteristics of ferric adriamycin complexes. Cancer Chemother. Pharmacol. 1984, 12, 5-9.
19. Myers, C. E.; Gianni, L.; Simone, C. B.; Klecker, R.; Green, R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 1982, 21, 1707-1713.
20. Beraldo, H.; Garnier-Suillerot, A.; Tosi, L.; Lavelle, F. Iron(III)-adriamycin and iron(III)-daunorubicin complexes: phyricochemical characteristics, interaction with DNA, and antitumor activity. Biochemistry 1985, 24, 284-289.
21. Gelvan, E.; Samuni, A. Reappraisal of the association between adriamycin and iron. Cancer Res. 1988, 48, 5645-5649.
22. Garnier-Suillerot, A. In Anthracycline and Anthracenedione-based Anticancer Agents; Lown, J. W., Ed.; Elsevier: Amsterdam, 1988; pp 121-162.
23. Muindi, J. R. F.; Sinha, B. K.; Gianni, L.; Myers, C. E. Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Lett. 1984, 172, 226-230.
24. Matzanke, B. F.; Bill, E.; Butzlaff, C.; Trautwein, A. X.; Winkler, H.; Hermes, C.; Nolting, H.-F.; Barbieri, R.; Russo, U. Evidence for polynuclear aggregates of ferric daunomycin. A Mössbauer, EPR, X-ray absorption spectroscopy and magnetic susceptibility study. Eur. J. Biochem. 1992, 207, 747-755.
25. 57Fe Mössbauer and electronic spectroscopies. J. Inorg. Biochem. 1997, 65, 115-122.
26. Gallois, L.; Fiallo, M.; Garnier-Suillerot, A. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroïsm study. Biochim. Biophys. Acta 1997, 1370, 31-40.
27. Fiallo, M. M. L.; Tayeb, H.; Suarato, A.; Garnier-Suillerot, A. Circular dichroism studies on anthracycline antitumor compounds. Relationship between the molecular structure and the spectroscopic data. J. Pharm. Sci. 1998, 87, 967-975.
28. Mankhetkorn, S.; Dubru, F.; Hesschenbrouck, J.; Fiallo, M.; Garnier-Suillerot, A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug resistant K562 cells. Mol. Pharmacol. 1996, 49, 532-539.
29. Koch, T. S.; Rava, R. P. Interpreting the visible absorption bands of 1,4-(dihydroxo)-9,10-anthraquinone and its metal chelates. Biophys. Chem. 1990, 36, 187-199.
30. Raymond, K. N.; Müller, G.; Matzanke, B. F. Complexation of iron by siderophores. A review of their solution and structural chemistry and biological functions. Top. Curr. Chem. 1984, 123, 49-102.
31. 21
32. Razzano, G., Rizzo, V.; Vigevani, A. Determination of phenolic ionization constants of anthracyclines with modified substitution pattern of anthraquinone chromophore. Farmaco 1990, 45, 215-222.
33. Pereira, E.; Fiallo, M. M. L.; Garnier-Suillerot, A.; Kiss, T.; Kozlowski, H. Impact of aluminum ions on adriamycin-type ligands. Dalton Trans. 1993, 455-459.
34. Tayeb-Bel Haj, H.; Fiallo, M.; Garnier-Suillerot, A.; Kiss, T.; Kozlowski, H. Anthracycline anticancer drugs as effective ligands for terbium(III) ions. Dalton Trans. 1994, 3689-3693.
35. 1H NMR relaxation study. J. Am. Chem. Soc. 1984, 106, 6905-6909.
36. Ming, L.-J.; Wei, X. An ytterbium(III) complex of daunomycin, a model metal complex of anthracycline antibiotics. Inorg. Chem. 1994, 33, 4617-4618.
37. Massoud, S. S.; Jordan, R. B. Complexation of aqueous iron(III) by daunomycin, quinizarin and quinizarin-2-sulfonate. Inorg. Chem. 1991, 30, 4851-4856.
38. Maroney, M. J.; Day, R. O.; Psyris, T.; Fleury, L. M.; Whitehead, J. P. Structural model for the binding of iron by anthracycline drugs. Inorg. Chem. 1989, 28, 173-175.
39. 3+ coordination sphere for an octahedral arrangement.
40. Sillen, L. G.; Martell, A. E. In Stability Constants of Metal-ion Complexes; The Chemical Society, Burlington House: London, 1964.
41. Fiallo, M. M. L.; Garnier-Suillerot, A. Copper(II)-anthracyline systems. Evidence of a dihydroxo-bridged-dicopper(II) aclacicnomycin complex. J. Inorg. Biochem. 1987, 31, 43-55.
42. Lynch, J. B.; Juarez-Garcia, C.; Münck, E.; Que, L. Mössbauer and EPR studies of the binuclear iron center in ribonucleotide reductase from Escherichia coli. J. Biol. Chem. 1989, 264, 8091-8096.
43. Cheesman, M. R.; Kadir, F. H. A.; Al-Basseet, J.; Al-Massad, F.; Farrar, J.; Greenwood, C.; Thomson, A. J.; Moore, G. R. EPR and magnetic circular dichroism spectroscopic characterization of bacterioferritin from Pseudomonas aeruginosa and Azobacter vinelandii. Biochem. J. 1992, 286, 361-367.
44. Aisen, P.; Leibman, A.; Zweier, J. Stoichiometric and site characteristics of the binding of iron to human transferrin. J. Biol. Chem. 1978, 253, 1930-1937.
45. Fiallo, M.; Laigle, A.; Borrel, M.-N.; Garnier-Suillerot, A. Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium with sensistive and resistant cells. Biochem. Pharmacol. 1993, 45, 659-665.
46. 3+ binds anthracycline antitumor compounds. The myth and the reality of a chemical sphinx. J. Inorg. Biochem. 1999, in press.